Toleranzia AB today publishes its annual report and auditors' report for the financial year 2023. The reports are available on the company's (www.toleranzia.se) and Nasdaq First North Growth Markets' (www.nasdaqomxnordic.com) websites.

For further information, please contact
Charlotte Fribert - CEO, Toleranzia AB
Tel: +46 763 19 98 98
Email: charlotte.fribert@toleranzia.com
 
About Toleranzia AB (publ)
Toleranzia AB (publ) develops drugs that utilize the immune system's own power to treat autoimmune orphan diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, only reduce the symptoms. They have the potential to be the first long-acting or curative treatments that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, CA@mangold.se, is the company's Certified Adviser.

Attachments

Toleranzia AB Annual Report And Auditors Report 2023

© Modular Finance, source Nordic Press Releases